Deaths Linked to Counterfeit Drug
Two recent deaths associated with counterfeit versions of retatrutide, a new investigational medication for weight loss, have been reported to the FDA. This highlights the potential dangers of using unregulated products in the weight-loss industry.
GLP-1 Receptor Agonists and Adverse Events
Current lawsuits claim that GLP-1 receptor agonists can lead to severe adverse events, emphasizing the need for continuous monitoring and regulation of these medications.
WHO Guidelines on Obesity Treatment in Children
The World Health Organization has released its first-ever guidelines regarding obesity in children and adolescents, advising against the use of weight-loss drugs or bariatric surgery for individuals younger than 10 years, stressing the importance of cautious approaches in pediatric care.
Positive Results from Petrelintide
Zealand Pharma reported that its investigational amylin analog, petrelintide, resulted in an average weight reduction of 9.2% at 28 weeks in a phase II trial involving adults with overweight or obesity and type 2 diabetes, showing promise as a treatment option.
Wegovy Gains Popularity
After the authorization of oral semaglutide (Wegovy) for weight management, new prescriptions exceeded 100,000 in just two months, indicating a high demand for effective weight-loss alternatives.
Discontinuation of Saxenda
Due to declining sales, Novo Nordisk announced plans to discontinue its GLP-1 injectable liraglutide (Saxenda) in early 2027, reflecting the dynamic nature of the obesity treatment market.
New Data on Tirzepatide
Recent phase IIIb trial data demonstrated favorable biomarker changes and decreased inflammatory immune activity with tirzepatide (Zepbound) and ixekizumab (Taltz) among adults with obesity and moderate-to-severe plaque psoriasis, indicating potential additional benefits of these drugs.
PMOS and Increased Dementia Risk
Research suggests that dementia and Alzheimer’s disease may occur more frequently in women with polyendocrine metabolic ovarian syndrome (PMOS), a finding likely associated with underlying metabolic issues that warrant further investigation and awareness.
Failure of Efzimfotase Alfa Trial
The investigational enzyme replacement therapy efzimfotase alfa did not achieve its primary endpoint in improving the 6-Minute Walk Test among treatment-naive patients with hypophosphatasia, highlighting the challenges in developing effective therapies.
Thyroglobulin Threshold Implications
Applying the new thyroglobulin threshold set by the American Thyroid Association has resulted in more accurate classifications of
Fuente: https://www.medpagetoday.com/endocrinology/generalendocrinology/123389
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
